- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- July 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- January 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- June 2025
- 147 Pages
Global
From €4397EUR$4,900USD£3,859GBP
- Report
- January 2025
- 135 Pages
Global
From €2287EUR$2,549USD£2,008GBP
€2691EUR$2,999USD£2,362GBP
- Report
- August 2024
- 233 Pages
Global
From €5707EUR$6,360USD£5,009GBP
€7134EUR$7,950USD£6,261GBP
- Report
- January 2024
- 395 Pages
Global
From €5384EUR$6,000USD£4,725GBP
€6730EUR$7,500USD£5,907GBP
- Report
- May 2024
- 128 Pages
Global
From €4957EUR$5,524USD£4,351GBP
€5832EUR$6,499USD£5,118GBP
- Report
- November 2023
- 139 Pages
Global
From €3993EUR$4,450USD£3,505GBP
- Report
- November 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,087GBP
Rufinamide is a medication used to treat seizures associated with Lennox-Gastaut syndrome, a rare form of epilepsy. It is classified as an anticonvulsant and works by decreasing the number of abnormal electrical signals in the brain. Rufinamide is typically used in combination with other anticonvulsants to control seizures. It is available in tablet and oral suspension form.
Rufinamide is a relatively new drug in the Central Nervous System (CNS) drugs market. It is used to treat a rare form of epilepsy, making it a niche drug. It is typically used in combination with other anticonvulsants, which can help to reduce the risk of side effects.
Several companies are involved in the Rufinamide market, including Eisai, Inc., Sun Pharmaceutical Industries Ltd., and Mylan N.V. These companies manufacture and distribute the drug in various countries around the world. Show Less Read more
